Baiju R. Shah, Chairman
Mr. Shah is Chief Executive Officer of BioMotiv and co-leader of The Harrington Project for Discovery & Development. Prior to BioMotiv, he was President and CEO of BioEnterprise; during Mr. Shah's tenure, the initiative assisted in the creation, recruitment, and acceleration of more than 110 bioscience companies in Cleveland that collectively attracted $1.3 Billion in new funding. He has been named an Ernst & Young Entrepreneur of the Year and has been recognized as one of Cleveland's most influential leaders. He received a J.D. from Harvard Law School and a B.A. from Yale University.
Ted Torphy, PhD
Ted Torphy, Ph.D., is the Chief Scientific Officer of BioMotiv and Chair of the Cystic Fibrosis Foundation Therapeutics, Inc. Dr. Torphy brings over 30 years of experience in the pharmaceutical Industry, including at Johnson & Johnson and SmithKlineBeecham, with a succcessful record in both small-molecule and large-molecule drug discovery.
Brian, project director for BioCrossroads, has a strong background in life sciences market development, and is responsible for identifying and developing opportunities for growth within Indiana’s life sciences sector. He authors reports and performs market research on the industry and supports the City of Indianapolis’ and State’s economic development by providing market information to attract and grow life sciences companies. Brian led the formation of the Central Indiana Corporate Partnership’s AgriNovus Indiana, a nonprofit established in 2013 to leverage Indiana’s strengths in agricultural innovation, working with industry CEOs, Indiana’s Lieutenant Governor and Purdue University to launch the new entity, publish a first-of-its-kind report and support early-stage ag-tech companies. In addition, he serves as an advisor to Indiana Seed Fund II. He currently serves on the boards of Algaeon and Allinaire Therapeutics, and former board roles include Aarden Pharmaceuticals and AgeneBio. He is a founder of Indy Science Connect, a life sciences industry - university networking organization. Prior to joining BioCrossroads, Brian was employed by Eli Lilly and Company in Corporate Affairs, where he ran the company’s political action committee. He also worked as a Senior Analyst in the company’s biotechnology unit and was a member of the team that established Lilly Systems Biology, Ltd. in Singapore. Previously, Brian was a manager in Arthur Andersen’s Assurance practice, providing audit and tax consulting to companies in the energy, telecommunications and healthcare industries.